[go: up one dir, main page]

TN2009000028A1 - Agonistes de ep2 - Google Patents

Agonistes de ep2

Info

Publication number
TN2009000028A1
TN2009000028A1 TN2009000028A TN2009000028A TN2009000028A1 TN 2009000028 A1 TN2009000028 A1 TN 2009000028A1 TN 2009000028 A TN2009000028 A TN 2009000028A TN 2009000028 A TN2009000028 A TN 2009000028A TN 2009000028 A1 TN2009000028 A1 TN 2009000028A1
Authority
TN
Tunisia
Prior art keywords
agonists
compounds
processes
preparation
methods
Prior art date
Application number
TN2009000028A
Other languages
English (en)
Inventor
Ganesh Prasanna
Charles Floyd Bosworth
Fontaine Jennifer Anne La
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TN2009000028A1 publication Critical patent/TN2009000028A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention propose des agonistes de EP2 des procédés pour leur préparation, des compositions pharmaceutiques contenant ces composés, et des méthodes d'utilisation de ces composés et compositions pour abaisser la pression intraoculaire et traiter ainsi Ie glaucome.
TN2009000028A 2006-07-28 2009-01-26 Agonistes de ep2 TN2009000028A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US94192307P 2007-06-04 2007-06-04
PCT/IB2007/002044 WO2008015517A2 (fr) 2006-07-28 2007-07-16 Agonistes de ep2

Publications (1)

Publication Number Publication Date
TN2009000028A1 true TN2009000028A1 (fr) 2010-08-19

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2009000028A TN2009000028A1 (fr) 2006-07-28 2009-01-26 Agonistes de ep2

Country Status (25)

Country Link
US (2) US7622475B2 (fr)
EP (1) EP2059507B1 (fr)
JP (1) JP4583500B2 (fr)
KR (1) KR101088942B1 (fr)
AP (1) AP2009004754A0 (fr)
AR (1) AR062122A1 (fr)
AU (1) AU2007280130B2 (fr)
BR (1) BRPI0714683A2 (fr)
CA (1) CA2659184C (fr)
CL (1) CL2007002207A1 (fr)
CR (1) CR10554A (fr)
EA (1) EA200970067A1 (fr)
EC (1) ECSP099071A (fr)
GT (1) GT200700064A (fr)
IL (1) IL196355A0 (fr)
MA (1) MA30604B1 (fr)
MX (1) MX2009001062A (fr)
NO (1) NO20090738L (fr)
NZ (1) NZ573964A (fr)
PE (1) PE20080408A1 (fr)
RS (1) RS20090002A (fr)
TN (1) TN2009000028A1 (fr)
TW (1) TWI372757B (fr)
UY (1) UY30511A1 (fr)
WO (1) WO2008015517A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2264009T3 (pl) * 2008-03-12 2019-07-31 Ube Industries, Ltd. Związek stanowiący kwas pirydyloaminooctowy
KR101681347B1 (ko) 2009-03-30 2016-11-30 우베 고산 가부시키가이샤 녹내장의 치료 또는 예방을 위한 의약 조성물
WO2011030865A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques substitués
AU2010293406A1 (en) * 2009-09-11 2012-05-03 Ube Industries, Ltd. Aniline compounds
WO2011030871A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés hétéroaryle n-substitués
WO2011030868A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés carbonyle substitués
WO2011030873A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés benzyliques
WO2011030872A1 (fr) * 2009-09-11 2011-03-17 宇部興産株式会社 Composés sulfonamide
JPWO2011078303A1 (ja) 2009-12-25 2013-05-09 宇部興産株式会社 アミノピリジン化合物
CA2808407A1 (fr) * 2010-08-17 2012-02-23 Allergan, Inc. Agonistes ep2 ou ep4 destines au traitement du voile corneen
KR20140097127A (ko) 2011-09-16 2014-08-06 포비어 파마수티칼스 아닐린 유도체, 그의 제조법 및 그의 치료 용도
HK1198514A1 (en) * 2012-01-20 2015-05-15 Acucela, Inc. Substituted heterocyclic compounds for disease treatment
CA2867527A1 (fr) 2012-05-03 2013-11-07 Takeda Gmbh Nouveaux agonistes du recepteur ep2
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
HK1219103A1 (en) * 2013-03-28 2017-03-24 Ube Industries, Ltd. Substituted biaryl compound
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
AR105215A1 (es) * 2015-07-01 2017-09-13 Santen Pharmaceutical Co Ltd Formulación de depósito que contiene ésteres de ácido cítrico
KR102481354B1 (ko) 2016-03-04 2022-12-23 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 프로스타글란딘 e2를 이용한 근육 재생을 위한 조성물 및 방법
KR102698911B1 (ko) 2017-06-09 2024-08-23 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 근육 질환을 예방하거나 치료하기 위한 조성물 및 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (fr) * 1998-06-23 2002-07-24 Pfizer Products Inc. Méthode de traitement du glaucome
EP1108426A3 (fr) 1999-12-02 2002-10-02 Pfizer Products Inc. Utilisation d'agonistes des prostaglandines pour traiter les troubles de l'érection et l'impotence
US20020115695A1 (en) 2000-11-07 2002-08-22 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
AU2002348948A1 (en) * 2001-11-30 2003-06-10 Pfizer Products Inc. Pharmaceutical compositions and methods for administering EP2 receptors selective agonists
CN1625549A (zh) * 2002-01-31 2005-06-08 辉瑞产品公司 (3－{[4－叔丁基－苄基)－(吡啶－3－磺酰基)－氨基]－甲基}－苯氧基)－乙酸的代谢物
WO2004078169A1 (fr) 2003-03-04 2004-09-16 Pfizer Products Inc. Utilisation d'agonistes selectifs du recepteur ep2 dans un traitement medical
US20050203086A1 (en) * 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Also Published As

Publication number Publication date
BRPI0714683A2 (pt) 2013-03-26
TWI372757B (en) 2012-09-21
EA200970067A1 (ru) 2009-08-28
JP4583500B2 (ja) 2010-11-17
CR10554A (es) 2009-02-10
EP2059507A2 (fr) 2009-05-20
JP2009544751A (ja) 2009-12-17
EP2059507B1 (fr) 2013-03-20
WO2008015517A2 (fr) 2008-02-07
ECSP099071A (es) 2009-02-27
WO2008015517A3 (fr) 2008-06-12
NZ573964A (en) 2010-11-26
US20100105905A1 (en) 2010-04-29
US7622475B2 (en) 2009-11-24
MA30604B1 (fr) 2009-07-01
AP2009004754A0 (en) 2009-02-28
CA2659184C (fr) 2012-02-21
IL196355A0 (en) 2009-09-22
AU2007280130B2 (en) 2011-09-22
CL2007002207A1 (es) 2008-02-01
AR062122A1 (es) 2008-10-15
TW200817360A (en) 2008-04-16
PE20080408A1 (es) 2008-04-28
NO20090738L (no) 2009-04-27
AU2007280130A1 (en) 2008-02-07
KR101088942B1 (ko) 2011-12-01
HK1133876A1 (en) 2010-04-09
KR20090023507A (ko) 2009-03-04
CA2659184A1 (fr) 2008-02-07
RS20090002A (sr) 2010-06-30
MX2009001062A (es) 2009-02-06
UY30511A1 (es) 2008-02-29
GT200700064A (es) 2009-06-18
US20080045545A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
TN2009000028A1 (fr) Agonistes de ep2
MA35576B1 (fr) Nouveaux composés
TN2011000454A1 (fr) Derives de benzofurannyle utilises comme inhibiteurs de glucokinase
TNSN08139A1 (fr) Composes therapeutiques
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA31419B1 (fr) Derives de pyridine
MA32471B1 (fr) Composés de borates esters et compositions pharmaceutiques contenant des composés
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
TN2010000230A1 (fr) Agonistes nouveaux des recepteurs de glucocorticoides
MA34207B1 (fr) Inhibiteurs de la pi3 kinase et/ou du mtor
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA31087B1 (fr) Derives d'amide et d'ester d'indazolyle pour traiter des troubles medies par le recepteur de glucocorticoïde.
MA32351B1 (fr) Derives d'aminodihydrothiazine a titre d'inhibiteurs de bace pour le traitement de la maladie d'alzheimer
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA33467B1 (fr) Promédicaments comprenant un conjugué insuline-lieur
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
MA31953B1 (fr) Nouveaux derives du thiophene.
MA31683B1 (fr) Composes et procedes pour moduler fxr
TNSN08137A1 (fr) Derives de carboxamides servant d'antagonistes des recepteurs muscariniques
MA30629B1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA33533B1 (fr) Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA49127B1 (fr) Dérivés d'indole n-substitués